The PPAR signaling and GLP-1 are mutually influenced and have similar effects on insulin release, β cell protection, cardiovascular benefits, and treatment of NAFLD, etc. Moreover, the mechanism of SGLT-2i as a novel insulin-independent medication was also discussed in the present review. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.